Tyr Pharma stock rated Hold after mixed trial results for efzofitimod; promising secondary data, but there remains uncertainty. Find out why ATYR is a Hold.

Marqeta is evolving with record EBITDA, strong TPV growth, and global expansion, though cash flow execution remains key. See ...

Loyalty is no longer something you buy. It is something you build. As more Gen-Zers come of age and Gen-Alpha starts to ...